← Browse by Condition
Medical Condition

diffuse intrinsic pontine glioma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for diffuse intrinsic pontine glioma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — diffuse intrinsic pontine glioma Clinical Trials

How many clinical trials are currently recruiting for diffuse intrinsic pontine glioma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for diffuse intrinsic pontine glioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diffuse intrinsic pontine glioma?
diffuse intrinsic pontine glioma research spans Phase 1 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diffuse intrinsic pontine glioma clinical trial?
Eligibility criteria for diffuse intrinsic pontine glioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 3
1
Top Sponsors
Capital Medical University 1 trial
Bambino Gesù Hospital and Research Institute 1 trial
Chulalongkorn University 1 trial
Gustave Roussy, Cancer Campus, Grand Paris 1 trial

Recruiting Clinical Trials

NCT05717712 Phase 1
Recruiting
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
Enrollment
18 pts
Location
China
Sponsor
Capital Medical University
View Trial →
NCT05298995 Phase 1
Recruiting
GD2-CAR T Cells for Pediatric Brain Tumours
Enrollment
54 pts
Location
Italy
Sponsor
Bambino Gesù Hospital and Rese...
View Trial →
NCT06221553 Phase 1
Recruiting
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
Enrollment
9 pts
Location
Thailand
Sponsor
Chulalongkorn University
View Trial →
NCT05476939 Phase 3
Recruiting
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Enrollment
433 pts
Location
Denmark, France, Spa...
Sponsor
Gustave Roussy, Cancer Campus,...
View Trial →

Related Conditions

oncolytic virus (1) adverse drug event (1) brain tumor pediatric (1) medulloblastoma childhood (1) embryonal tumor (1) high grade glioma (1) diffuse midline glioma (1) brain tumor adult (1) dipg brain tumor (1) diffuse midline glioma h3 k27m mutant (1) diffuse midline glioma h3k27 altered (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology